Vision. Expertise. Success.
AbbVie Contract Manufacturing partners with companies across the globe to develop, scale and manufacture pharmaceutical products and bring them successfully to market.

Drawing on more than four decades of success as the manufacturing division of AbbVie, we have the depth of experience and the technical knowledge to navigate issues and deliver the innovative solutions customers need. We are much more than a CMO – we are your partner for success.

With foresight, scientific expertise, and passion we anticipate the technical and compliance challenges along the entire pharmaceutical development journey through to commercialization. We see the complete picture to deliver our customer's vision.

With full access to global state-of the-art facilities and world-class talent, our customers have come to depend on our service and quality to deliver real-world results.

Visit abbviecontractmfg.com for more information.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. We have developed and manufactures more than 65 products sold by customers worldwide.

We have the expertise and proven track record to guide projects from clinical research stages through optimization, validation, and approval. We operate seven facilities in the US and Europe, equipped to facilitate efficient drug product development and manufacturing, maintaining excellent environmental conditions compliant with US and EU cGMP regulations.

Adare has dedicated high potency GMP manufacturing and development areas. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care.

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong™, a long-acting peptide platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

amofor is a leading science-driven formulation development company specializing in predictive design of complex drug delivery systems. amofor creates digital twins of formulations (e.g. amorphous solid dispersions or lipid-based drug delivery systems), allowing scientists to understand, predict, and optimize complex drug delivery products at the molecular level.
As a trusted partner to leading pharmaceutical companies, amofor supports the development of advanced formulations and provides cutting-edge software solutions for predictive formulation design. By replacing empirical trial-and-error with a rational, physics-based approach, the company accelerates development timelines, reduces experimental effort, and enhances robustness in pharmaceutical and life science applications.

Aprecia is the biopharmaceutical leader in advanced additive manufacturing technologies. As a specialty CDMO,
we help you overcome formulation challenges. Through novel oral dosage forms, we are reimagining medicine so patients and caregivers can live their best lives.

We are Ardena, a reputable contract partner delivering drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with you to compile your regulatory dossier and to fast track your product towards compliance. Every day, we guide companies through the hurdles and challenges of drug development. Our integrated service offering helps to streamline the drug's progress to clinic and beyond. Ardena is your one source contractor for the chemical and pharmaceutical development of your valued compounds. In parallel, we provide you with full product analytical and bioanalytical support during development. Our dossier-centric approach makes a difference. We work with you to compile your regulatory dossier in parallel with drug development, saving you time, identifying hurdles and fast-tracking your product to compliance. We are experts in writing and formatting supporting CMC documentation.

Asahi Kasei is a highly diversified Japanese supplier of high-performance materials for various industries, including automotive, energy, electronics, housing and health care. In the fields of pharma- and nutraceuticals, we offer functional excipients. For many decades Asahi Kasei stands for quality, reliability and performance and is dedicated to “Creating for Tomorrow”.

Our key product is Ceolus, functional grades of microcrystalline cellulose (MCC) with outstanding compactability and flowability due to a special particle structure. This allows for avoiding typical formulation challenges like tablet mass segregation, capping, slow/fast disintegration, low tablet hardness or the changing of the API structure. Celphere, Asahi Kasei’s MCC spherical cores allow the combination of incompatible APIs in one tablet, achieve different release profiles and improve the acceptability of products. Special grades of our pregelatinized starch PC-10 can be applied for the protection of moisture sensitive APIs in the formulation.

Our functional excipients prove to be solutions to our customer’s daily challenges.

Ashland works alongside formulators to advance drug-specific delivery platforms with an industry-leading portfolio of pharmaceutical excipients and technical expertise including superior polymer technology and systems for optimum bioavailability.

For over 50 years, Ashland has created value for customers through applications knowledge, technical support, and a powerful product portfolio. The company offers real-time solutions based on superior binder, film coating, solubilizer, disintegrant, rheology control, cyclodextrins and modified-release technologies.

A team of technical experts at global R&D centers provide formulation development support for conventional and potent compounds as well as controlled substances to offer tailored solutions that address solubility challenges.

During this event, Ashland will showcase polymer solutions for extended release injectable depot strategies including ViatelTM bioresorbable polymers. This portfolio includes 72 GMP grades of lactide, glycolide and caprolactone copolymers as well as a customized polymer platform which supports formulators to solve complex processing, stability and delivery challenges.

Founded in 2007, AustinPx is a fee-for-service CDMO offering preclinical through Phase II formulation and process development and GMP manufacturing of oral dosage forms. We specialize in bioavailability enhancement, speed to clinic and market development strategies, and dose form development.

The name AustinPx represents where we come from and what we do. Px stands for Pharmaceutics. To our core, we are a pharmaceutics company. Our approach is data-driven and agnostic which means our formulation strategy for each drug is based on the unique physiochemistry of that compound. And for poorly soluble compounds, we have one of the most powerful tools available in KinetiSol®, a truly next generation technology for rendering active pharmaceutical ingredients amorphous.

KinetiSol™ Technology
The KinetiSol Technology generates amorphous solid dispersions (ASD), dramatically improving the bioavailability of poorly soluble drugs. KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies- in a fraction of the time of other ASD technologies. With its significantly smaller ecological footprint, broader formulation design space, faster processing times and wider applications to challenging molecules, KinetiSol is the next generation amorphous dispersion technology.

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Focusing On Your Formulation Needs

BASF produces excipients and active ingredients of outstanding quality and performance. With our unique expertise in polymer chemistry, our research & development capabilities and our clear commitment to developing excipients, BASF has continuously created solutions that contribute to your success and to more efficient pharmaceuticals. We deliver value added functional solutions to your formulation challenges by leveraging our expertise in delivery systems and related technologies. Our team of experienced industry specialists support you in developing effective, reliable formulations – giving you a vital advantage in a highly competitive market.

Our Platforms – Your Access To BASFs Solution Offer

BASF has been committed to the pharmaceutical industry since we introduced our original Kollidon® in the early 20th century. Since then we have continuously expanded our solution offer. Today we solve unmet formulation needs and offer intelligent solutions for today and tomorrow's challenges in drug formulation. Our four dedicated solution platforms based on current pharmaceutical market needs help you to find what you are looking for – faster than ever before. We can help with formulation challenges related to Instant and Modified Release, Solubilization, Skin Delivery, Softgels and Biologic Solutions

BIONANOPHARMA, part of the Insud Pharma Group, is a drug delivery company with an EU-GMP–approved facility specializing in electronebulization and electrospinning.

Our patented technology platform enables tailored drug release profiles in fiber or powder form, using room-temperature processing—ideal for thermally sensitive biologics (mAbs, ADCs, proteins, enzymes, RNA, vaccines) and complex small molecules (oligonucleotides, peptides).

Fiber formats support buccal, sublingual, transdermal, and ophthalmic patches, as well as orally dissolving films and inserts. Our powders are engineered to enhance the bioavailability of BCS Class II, III, and IV APIs, and are suitable for oral dosage forms, inhalation, nasal delivery, and long-acting injectables.

The process is fully scalable, uses commercially available pharma-grade excipients, and supports batch sizes from milligrams to tonnes—ensuring flexibility from early development to commercial production.

Cambridge Design Partnership is a design and engineering consultancy with R&D centers in the UK and the US. We create breakthrough products and services for global brands and ambitious start-ups across healthcare, consumer, and industrial sectors. Our multi-disciplinary teams unite scientific rigor, design ingenuity, and engineering excellence to accelerate time to market. Our drug delivery team is trusted to innovate solutions for parenteral, respiratory/nasal, sublingual, transdermal, and novel routes like ocular, brain, and direct-to-organ delivery.

Capsugel provides high-quality capsules and innovative solutions for oral drug delivery and inhalation. Capsugel's expertise supports the optimization of formulations, offering tailored technologies and services to advance pharmaceutical and nutraceutical development worldwide. Capsugel's global network includes complete supply chain, regulatory, quality and application support to meet your needs with capsule manufacturing facilities in North America, Europe, India, China and Japan. Capsugel offers full lifecycle development and manufacturing (CDMO) for oral and inhalation drug products.

Find out more at www.capsugel.com
Follow @Lonza Capsules & Health Ingredients on LinkedIn

Catalent specialises in comprehensive development, analytical and bioavailability enhancement from candidate selection to fully integrated solutions, to help get customers’ drugs to clinic faster. Using a rigorous, data-driven scientific approach, API-sparing techniques and advanced formulation technologies within a global network, Catalent helps solve complex challenges to accelerate drug development.

Celanese offers the VitalDose® Drug Delivery Platform, providing long-acting controlled release of small molecules, biologics, and nucleotides through implant and insert dosage forms. Work together with Celanese experts in our state-of-the-art feasibility lab for customized materials and service solutions tailored to your application—helping you establish proof of concept.

We are equipped to create functional API-loaded prototypes, characterize and measure in vitro drug release, and provide technical transfer support to our customers and their partners. Backed by years of experience working with global regulatory bodies, we provide customers with relevant certifications and documentation needed throughout various stages of their drug development and approval process.

With decades of experience in medical and pharmaceutical applications, our customers trust us to provide unrivaled service, world-class expertise, and quality that improve product development, enhance manufacturability, and elevate patient experiences.

Learn more about our solutions and capabilities at healthcare.celanese.com.

CLADE provides advanced analytical tools that help biopharma rapidly characterise formulations across multiple attributes - in development, QC and bioprocessing workflows. The MIRA Analyzer delivers high performance mid infrared FTIR spectroscopy, while Sphere enables easy data processing. Together, they offer multi attribute, high throughput analysis that can replace multiple methods and saves significant time.

Codis is a global CDMO with world class manufacturing capabilities and deep expertise in spray drying, amorphous solid dispersions (ASD), and particle engineering technologies. Formed through the integration of Particle Dynamics in the US and the Haverhill, UK facility previously operated by EUROAPI, Codis unites decades of regulatory excellence, technical innovation, and commercial manufacturing strength under one brand. Our Haverhill site located near Cambridge, UK, is a purpose built, continuously upgraded pharmaceutical manufacturing facility with a long standing track record in global supply. Specializing in complex APIs, co processed excipients, and spray dried amorphous dispersions, the site operates with full cGMP compliance, robust environmental controls, and a strong safety culture.

Corealis Pharma offers complete formulation development and clinical supply manufacture of pharmaceutical oral solid dosage forms for US, European and Canadian submissions. Each project is different and Corealis experts select the most suitable formulation and manufacturing process train for each drug substance as per its intended application. They have in-house access to well-equipped, state of the art R&D and GMP compliant operations such as API characterization, spray drying, hot melt extrusion, solid dispersion, high shear granulation, fluid-bed granulation/ drying/ coating, roller compaction, melt granulation, extrusion/spheronization, pan coating, tableting, encapsulation, packaging, patient kits preparation, warehousing, distribution and analytical services. This means that when Corealis professionals commit to a delivery date and budget, they have all the tools and resources needed to stand by their commitments and the ability to adjust quickly to any changes that may occur in the execution of a project.

Coriolis Pharma is a globally active, science driven contract research and development organization (CRDO) and a premier partner for drug product development, analytical services, and manufacturing across a broad range of biological therapeutic modalities. With deep expertise in both liquid and lyophilized drug products, Coriolis’ scientists design and execute platform and customized services that accelerate and de risk client programs from the very beginning and throughout the entire product lifecycle.

Coriolis Pharma distinguishes itself through scientific excellence, innovative analytical approaches, and a profound understanding of formulation and drug product development. The company is headquartered in Martinsried, Germany, and operates a U.S. facility in the Research Triangle of North Carolina.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Curia’s network of sterile drug product facilities support partners from formulation development to commercial manufacturing in various formats including vials, pre-filled syringes, and cartridges. With over 30 years of experience formulating both large and small molecules for injection, you can rely on Curia.

Datwyler provides high-quality, system-critical elastomer components and has a leading position in the global healthcare market. Within the healthcare solutions business area, Datwyler develops, designs, and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future!

DelSiTech is a drug delivery and drug development company, based in Finland and is the leader in fully biodegradable, amorphous silica-based long-acting controlled release. DelSiTech's core technology, Silica Matrix, enables the delivery of virtually any API with truly controlled release over durations from a day to a year. DelSiTech Silica Matrix technology enables parenteral drug delivery through a wide variety of routes of administration, in addition to topical ocular applications of the patent protected silica composite technology. DelSiTech is currently developing controlled release products based on its Silica Matrix technology across a wide range of therapeutic areas for partners such as Bayer and the Bill & Melinda Gates Foundation

DFE Pharma is a global leader in the development, production and supply of high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, OSD, ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients. With more than a century of experience and around 450 people worldwide, we serve over 5,000 customers in 100+ countries. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies to improve patient’s lives, driven by our purpose: Your medicines, and our solutions. Moving to a healthier world.

digiM is a technology leader providing CRO services in microstructure analysis and in silico modeling for the development of drug products. Combining advanced microscopic analysis with computational physics, digiM's platform provides a full spectrum understanding of drug product properties and performance. digiM works closely with developers to navigate program challenges and institutionalize knowledge libraries. In addition to services, digiM provides I2S, a cloud-based image analytics and data management platform.

As innovators in nutrition, health, and beauty, we reinvent, manufacture, and combine vital nutrients, flavors, and fragrances for the world’s growing population to thrive.
In the Biomedical division, we serve as a committed partner in driving sustainable innovation in healthcare, from spark to solution. Our biomaterial products, customized solutions and expert services are recognized for their unmatched quality, reliability, and performance worldwide.
Together, we bring progress to life every day, everywhere, for billions of people.To learn more, visit

Eurofins CDMO is a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with Active Pharmaceutical Ingredients (APIs)/Drug Substance and Drug Product development for biologicals and small molecules. Science is our foundation and allows us to support small and major biopharmaceutical companies achieving their pre-clinical and clinical milestones on time.

We are experts in breakthrough technologies for API development, highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs…).

Our services: API/DS Development, Solid State R&D, Preformulation, Formulation Development, GMP Manufacturing, Clinical Packaging and Logistics, CMC Regulatory Support.

Our highly-qualified project management team will propose a complete drug development strategy. Frequent communication through one single point of contact, our team's flexibility, troubleshooting mindset, customized solutions will help speed up the drug development process. Operating under strict quality procedures, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

Evonik Health Care is a global leader in advanced drug delivery solutions, partnering with pharmaceutical and biopharmaceutical companies to bring innovative therapies to market.
With deep expertise in oral drug delivery, Evonik offers a comprehensive portfolio of EUDRAGIT® functional polymers and EUDRACAP® ready to fill capsules that enable immediate, delayed, controlled release, and targeted delivery performance.
In parenteral drug delivery, Evonik provides an extensive range of catalog lipids -including PhytoChol® plant derived cholesterol, PhytoSquene® plant based squalene, and ionizable, cationic, and PEG lipids - alongside custom lipid development and integrated formulation, scale up, and CDMO services.
For polymer based parenteral applications, Evonik is home to RESOMER® and LACTEL® bioabsorbable polymers, supporting long acting injectables such as microparticles, implants, and nanoparticles. As the only company combining PLG polymer manufacturing with formulation and drug product development, Evonik is uniquely positioned to enable the advancement of next generation parenteral therapies.

Since 1880, Gattefossé has developed and manufactured high-quality lipid excipients for human and animal health. Our oral excipients offer solubility/bioavailability enhancement, sustained release, lubrication, and taste-masking. We also provide solubilizers, penetration enhancers, emulsifiers, and viscosity enhancers for improved topical formulations, as well as suppository and pessary bases. All Gattefossé products are backed by comprehensive safety, quality, and regulatory documentation to support your formulation and manufacturing needs. To accelerate development, our team of highly trained experts offers hands-on support through four Technical Centers of Excellence located in France, China, India, and the United States.

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer psroduces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

Hovione offers customized services and innovative solutions from drug substance to drug product, with all activities performed at the same site. Hovione provides a fully integrated service for clinical and small commercial scale complex drug product development and manufacturing as well as formulation development for highly sophisticated inhalation and other formulations both for small molecules and biologics. As the Leader in Commercial Spray Drying, Hovione can handle projects from early-phase development to commercial and accelerates your time to market. Our particle engineering technologies can address challenges in solubility enhancement, lung delivery, modified release and taste-masking applications and can handle highly potent compounds. For biopharmaceuticals Hovione is investing by partnering in specialized particle engineering technologies, namely spray drying, aseptic spray freeze drying, nanoparticles and microemulsions. We do well what is difficult, to give our customers what they cannot find elsewhere

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long-acting injectables (LAI) for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Using biodegradable polymers for microspheres, gels and implants (including ISFI) we have a unique platform to control sustained drug delivery of small molecules, peptides and proteins (including mAbs) from days, weeks to months (6).

InnoGI Technologies is a renowned contract research organization (CRO) to service pharmaceutical and food & nutrition companies. We are highly specialized in gastrointestinal (GI) modeling. Our advanced in vitro and in silico approach (the TIM® Platform) simulates the entire GI tract, offering deep, data-driven insights into digestion, bioavailability/ADME, and microbiome interactions.

Intrepid Labs is the AI leader in pharmaceutical formulation science, dedicated to designing fit-for-purpose formulations faster, smarter, and more efficiently. Powered by decades of experience in formulation science and AIdriven automation, Intrepid Labs accelerates therapeutic development through its Valiant™ platform. This AI-driven, robotic lab compresses timelines from months to days, exploring the full formulation design space to deliver optimized, data-driven solutions supported by proprietary AI algorithms. The company is led by CEO and Co-Founder Dr. Christine Allen, a global expert in drug formulation with over 180 peer-reviewed publications. Together with co-founders Dr. Pauric Bannigan (Chief Scientific Officer) and Dr. Riley Hickman (Senior Director of Engineering), Intrepid’s leadership team leverages expertise in drug delivery, laboratory automation, and AI-driven pharmaceutical development. With multiple strategic collaborations and a growing pipeline, Intrepid sets a new standard for excellence in formulation, enabling faster, more precise, and cost-effective paths to transformative therapies.

Based on 60 years of experience in the development and manufacturing of scientific instruments, KNAUER also offers custom engineering of equipment for the laboratory and for GMP production.

The company’s most recent development in this field – lipid nanoparticles (LNP) production systems – have enabled the large-scale manufacturing of mRNA-based vaccines to fight the Corona pandemic.

Traditionally, KNAUER is best known for its high-precision liquid chromatography systems (HPLC and FPLC) and related components. The systems are used to analyze samples for ingredients and impurities and determine their quantities, both in the laboratory and in process analysis. The systems can also purify value substances such as active pharmaceutical ingredients on a laboratory scale.

KNAUER’s valves, pumps, detectors, and other components are also used for tasks such as high-pressure dosing and various flow detection tasks in different applications. OEM manufacturing LC components for other suppliers is an important part of KNAUER’s business.

Leukocare is a formulation development partner specializing in biologics, applying bioinformatics-driven preselection and empirical design to develop molecule-specific solutions. Our proprietary, data-guided approach accelerates identification of excipients and formulation parameters, reducing timelines and conserving drug substance.

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of approximately 18,500 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. We support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

As a trusted technology partner for the pharmaceutical industry, LTS develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Lubrizol provides excipients that enhance the solubility and bioavailability of active ingredients. Apinovex™ Polymers are used for amorphous solid dispersions, improving the solubility of poorly soluble drugs. Apisolex™ Polymers enhance solubility in injectable formulations, offering high drug loading and stability.

Carbopol® Polymers are high molecular weight polyacrylic acid polymers used in various formulations for their thickening and stabilizing properties. We also supply a range of other ingredients listed on the FDA’s Inactive Ingredient Database (IID) that can help improve the feel and performance of topical pharmaceutical formulations.

Merck, a leading science and technology company, unites our Millipore® and SAFC® products and services into a comprehensive portfolio that gives you the options needed to confidently solve your most urgent bio/pharmaceutical challenges.
Supported by advanced technical and regulatory expertise, our offering represents new opportunities for traditional and novel modalities, including process intensification and digital transformation. It will help you streamline complex decision-making, accelerate progress from process development through large-scale GMP production, and keep you aligned with evolving regulatory requirements.

We support every step of your product development and manufacturing from upstream and downstream to formulation with a broad portfolio that includes single-use assemblies and systems, technologies for filtration and purification, control and analytics software, process analytical technology, high-quality raw materials and excipients complemented by a tailored service offering.

No matter the modality, our options become your opportunities, empowering you to design a roadmap for efficient and scalable bio/pharmaceutical processes.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

Nanexa is a pioneering pharmaceutical company dedicated to the development of innovative drug delivery systems. At the forefront of its technological advancements is the PharmaShell® technology, designed for long acting injectables. This cutting-edge technology harnesses the power of nanotechnology to create a shell around the active pharmaceutical ingredient, enabling controlled and sustained release over extended periods. PharmaShell® holds the potential to transform treatment paradigms across various therapeutic areas by improving patient compliance, reducing dosing frequency, and enhancing efficacy. Nanexa’s commitment to innovation and excellence in drug delivery is underscored by its robust research and development efforts and strategic collaborations with industry leaders. As Nanexa presents PharmaShell® at this conference, it aims to showcase the technology’s capabilities and its impact on the future of long acting injectables, fostering new partnerships and advancing the field of pharmaceutical sciences.

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline to progress to clinical development. CESS® enables lower dosage and safer products to be developed with reduced side-effects and permits combination therapies, which would otherwise be prohibited by the large dosages of either drug. The award-winning technology is also ushering in a new era of ocular, pulmonary and transdermal drug delivery applications, along with enhanced delivery of drug particles across the blood-brain barrier.

Nisso Chemical Europe offers NISSO HPC, a high-quality excipient for the pharmaceutical industry providing hydroxypropyl cellulose in a wide range of viscosities and particle sizes for diverse applications, offering solutions for direct compression, roller compaction, wet granulation, drug solubility enhancement (amorphous solid dispersions, nanosuspensions), supersaturation stabilizer, controlled release hydrophilic matrix systems, 3D tablet printing, extrusion, orodispersible tablets, injectables, and film coating.

NovoArc is a Vienna-based biotech startup (founded in 2021) that develops and produces unique, highly stable ether-lipids for use in pharmaceutical drug formulation and delivery. These specialized lipids protect active pharmaceutical ingredients (APIs), namely small molecules, proteins, and nucleic acids, from degradation (e.g., in the stomach) and boost their bioavailability. NovoArc’s platform uses a patented biotechnological process to generate these ether lipids.

Nucleus Medical, founded in 2019, located in 82031 Grünwald, Bavariafilmplatz 7, Germany, is a scientific project development company. The company's core competence lies in the development of innovative buccal film formulations for poorly or insoluble active ingredients.

Drug delivery systems you can trust
Owen Mumford Pharma Services are leaders in the design, development, manufacture & sales of injectable drug delivery systems for the pharmaceutical, biotech and generics industries.
Find out how our pharma services can help destress your injectable journey to market.
Our DNA is to empower healthcare and improve lives with our trusted innovation through precision delivery.
Our drug delivery platforms have a comprehensive & targeted IP portfolio with wide freedom to operate
But its more than just innovation; we believe in partnerships, trust, and collaboration.
Discover our flagship single use subcutaneous autoinjector platform Aidaptus which has one form factor (one outer shell for 1ml and 225ml variants) to unlock manufacturing efficiency (self-levelling plunger story).
The EcoSafe safety syringe platform is modular, giving all patients confidence in self-administration, it’s smarter for budgets and kinder to the planet.

Pensatech Pharma GmbH (founded in Berlin, Germany in 2012) is a knowledge- and science- driven research and development company with a comprehensive suite of known and innovative drug delivery technologies. We focus on designing, developing and advancing dosage forms for new and existing drugs.

Our expertise includes oral modified-release systems such as granules, pellets, minitablets, osmotic and matrix tablets, as well as parenteral formulations including aqueous and oily solutions, micro- and nanosuspensions, microparticles, implants, liposomes, biodegradable polymeric and lipid carriers, and lyophilized products.

We also focus on local drug delivery, particularly ocular and topical applications, and offer a range of bioavailability and solubility enhancement technologies, including emulsions, micro- and nanosuspensions, solid dispersions, hot-melt extrusion, and spray-dried dispersions.

Our portfolio further covers stability improvement, formulations for highly potent APIs and cytotoxics, high-dose drug delivery, and the development of classical dosage forms such as tablets, capsules, coatings, solutions, suspensions, and gels.

Pfanstiehl Inc. is a cGMP Manufacturer of High Purity Low Endotoxin components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as L-Arginine, Histidine, Glutamine and Methionine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan Illinois USA. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

Pion Inc. offers unique instruments and services for informed drug and food formulation decisions, spanning R&D to manufacturing. Pioneering in vitro to in vivo tools, we optimize drug development and provide insights for pharmaceuticals and biopharmaceuticals. Our mission: expedite drug development, serving a global market with two decades of trusted expertise. Headquartered in Massachusetts, USA, and a UK office for global reach, Pion Inc. advances pharmaceuticals through innovation.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.

Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

Roquette unites the proven expertise of Roquette Pharma Solutions with the strengths of Qualicaps and IFF Pharma Solutions - bringing together over 75 years of innovation in excipients, APIs, capsules, and drug delivery systems.

We provide comprehensive solutions for controlled release, immediate release, solubility enhancement, and nitrosamine mitigation strategies - leveraging deep polymer expertise, technical excellence, and a strong commitment to sustainable, compliant manufacturing practices.

As a trusted partner and preferred supplier, we help formulators develop robust, high-performing products - faster and more effectively.

Sanner is a global medical device CDMO partner that excels at turning ideas into commercially viable products. We combine deep design engineering expertise, human-centred innovation, and world-class manufacturing to take medical, diagnostic and drug delivery concepts from paper to production with confidence and efficiency.
As part of our fully integrated service model, we lead every stage of the development journey - from early-stage concept development, feasibility and user research, through detailed design engineering, prototyping, verification & validation, to design transfer and scalable production readiness. Our process is built around manufacturability, regulatory alignment, and usability, ensuring seamless progress with fewer redesign cycles and lower risk.
Supported by decades of industry experience, a global manufacturing footprint spanning multiple continents, and a full suite of regulatory, manufacturing, packaging, and supply chain solutions, Sanner helps innovators accelerate time to market, mitigate risk, and scale with confidence - delivering high-quality, compliant medical devices that improve patient care worldwide.

Sartorius BIA Separations develops and manufactures market-leading CIM® monolithic chromatographic columns for the purification and analysis of large biomolecules, such as viruses, plasmids, mRNA and LNPs, which are applied in cell and gene therapies. The company’s Cornerstone® Biomanufacturing Development Services are the result of more than 25 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production while improving the safety of therapeutic products. Sartorius BIA's technology for manufacturing-scale purification is already used in the production of the first commercialized advanced therapeutics; the company also has a keen presence with novel drug candidates in the clinical pipeline.

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 650 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Seppic, an Air Liquide Healthcare company, has been a subsidiary of the Air Liquide Group since 1986. For over 75 years, Seppic has developed, manufactured, and marketed unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary, and industrial products. Across the world, Seppic has created a vast team of women and men who love what they do in service to their customers, and to the health, well-being, and beauty of all.

As an expert in surfactants, polymers, and formulation, Seppic offers pharmaceutical excipients adapted to oral, topical, and parenteral routes of administration. Its ingredients range from film coatings for tablets to injectable solubilizers and polymers for dermopharmacy. For over 25 years, Seppic has also offered high-performance adjuvants for therapeutic vaccines. Now, our work has expanded to involvement in prophylactic vaccines.

QPharma, Foster Delivery Science and Disphar International are now Sever Pharma Solutions. Together we have formed a new CDMO, a company that can provide our customers with unique capabilities and expertise. Sever Pharma Solutions brings your pharmaceutical ideas to life by offering expertise in high potent drug development, a drive to enhance performance, a passion for perfection, and a commitment to be your partner through the whole journey. We can enhance your reach by ensuring that your products can benefit patients all over the world. We can enhance your efficiency by providing you with a complete value chain to offer you an optimized end-to-end solution. We can enhance your product by adding value through all development and manufacturing processes. We can enhance your outcome by adding value through all development and manufacturing processes. We are Extrusion. We are Polymer Based Dosage Forms. We are Formulation of Highly Active dosage forms. We are Long Acting Implants. We are Solid Dosage Forms. We are Injection Molding. We are Aseptic Fill and Finish. We are Sever Pharma Solutions.

SE Tylose is the distribution organization of Shin-Etsu Chemical Co., Ltd. Japan and SE Tylose, Wiesbaden Germany and is registered in Wiesbaden. It is located at the Industrial Park Kalle-Albert in Wiesbaden. Together with our distributors, we are the exclusive business partners for our customers and multi national key accounts in the pharmaceutical- and the food industry. SE Tylose manages a regional, centralized warehouse for all products to be able to supply the customers in Europe on short-term base whenever necessary. SE Tylose will manage logistic for customers in other regions independent from Shin-Etsu´s production sites. For our pharma customers we offer with our technical application lab the possibility to optimize their processes if required. Our products are covering a very wide range of applications and they fully comply with FDA, USP/NF, JP and EP requirements. Pharmaceutical Excipients: Cellulose ether excipient is a pharmacologically inactive substance used as a carrier for the active ingredients in medication. PHARMACOAT® – Water-Soluble Film Coating Agent METOLOSE® – Binder and Thickening Agent METOLOSE® SR – Sustained release agent for hydrophilic matrix system L-HPC – Disintegrant with Binding Properties, Multifunctional Excipient HPMCP – Enteric Coating Agent Shin-Etsu AQOAT® – Enteric Coating Agent, Solid Dispersion Polymer Tylopur® – Low- and high viscosity Hypromellose

Siegfried is a globally leading outsourcing partner, providing tailor-made services that seamlessly integrate into the value chain of our customers. We offer contract development and manufacturing of APIs and finished dosage forms. Through our integrated approach we ensure a comprehensive range of services from process development and optimization to registration, production, packaging and logistics.
As a fully integrated CDMO, Siegfried is one of the few organizations today that can carry out the development and manufacturing of APIs and finished dosage forms under one roof. This unique combination of know-how and experience makes us the most trusted partner in the pharmaceutical industry.
Founded in 1873 in Zofingen, Switzerland, today we operate a global network of 12 sites on three continents. Our workforce of more than 3,700 highly skilled professionals is committed to take the innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide.

SPI Pharma is a global excipient and formulation solutions partner supporting the development and commercialization of innovative drug and vaccine products. We combine high-quality excipients with deep scientific and application expertise to help pharmaceutical companies address complex challenges across oral solid dose, chewables, effervescents, taste-masked systems, parenteral and nutraceutical applications.
Our portfolio includes functional excipients that enhance flow, compression, stability, and bioavailability, as well as well characterized vaccine adjuvants designed to support immune response and formulation performance. Backed by strong regulatory and quality systems, SPI Pharma works collaboratively with development teams to de risk programs, accelerate timelines, and enable patient centric drug delivery solutions.

Founded in 1949, Stevanato Group is a leading global provider ofdrug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. TheGroup delivers an integrated, end-to-end portfolio of products,processes and services that address customer needs across the entire drug lifecycle at each of the development, clinical andcommercial stages. Stevanato Group’s core capabilities in scientificresearch and development, its commitment to technical innovationand its engineering excellence are central to its ability to offer value-added solutions to clients.

Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, we help you – our customers in the global pharmaceutical and food industries – to improve people's lives. For that we look back on more than 160 years of experience. In the pharma sector, our intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of your liquid and solid pharmaceuticals. In the food industry, our flexible and reliable technologies produce and package confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for your smooth production processes. In everything we do, our more than 30 sites in almost 20 countries keep a firm eye on our impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions.

TTP applies science-led engineering to the development of advanced drug delivery systems, helping pharma and biotech teams translate complex formulations into robust, scalable products.

Working at the interface of formulation science and device design, we support challenging therapies across parenteral, respiratory and targeted delivery applications.

By combining deep scientific insight with engineering and human factors expertise, we help teams de-risk development and deliver reliable real-world performance.

Website: www.ttp.com

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions and AI-driven automation that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

WuXi STA, an integrated part of WuXi AppTec, is an industry-leading pharmaceutical development and manufacturing capability and technology platform serving the life sciences industry with operations across North America, Europe and Asia. As an innovative Contract Development, and Manufacturing Organization (CDMO) for small molecule new drug development, WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions from preclinical to commercial uses.

At XEDEV, we support your product development journey by combining extensive formulation and process expertise with state-of-the art manufacturing capacity.

We specialize in formulation and process development for solid drug products. Leveraging our extensive expertise, we design customized solutions to meet the requirements of each customer, ensuring advanced and efficient outcomes. Furthermore, XEDEV provides manufacturing services for R&D and GMP batches, supporting PK, Tox, Phase I and II clinical studies. Our flexible production capabilities range from small-scale to large-scale batch productions, accommodating your specific needs.

At XEDEV, we pride ourselves on being more than a service provider – we’re an extension of your team. With strong communication and collaboration at the core of our approach, we ensure a seamless and productive partnership. Contact XEDEV today to learn more about how we can support your development and manufacturing needs.

Find out more at www.xedev.com.

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.